argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
argenx will host a conference call on July 28, 2022, at 2:30 pm CET (8:30 am ET) to discuss its half-year 2022 financial results and provide a second quarter business update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
argenx will host a conference call on July 28, 2022, at 2:30 pm CET (8:30 am ET) to discuss its half-year 2022 financial results and provide a second quarter business update. Investors can access the live call via the Investors section of the argenx website. The call will include a webcast replay available for one year. Investors are encouraged to dial in 15 minutes early using access code 3810049 for efficient participation.
Details
News Market Reaction – ARGX
The recorded move for ARGX in the trading session of this news was +0.98%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
July 21, 2022
Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 28, 2022 at 2:30 pm CET (8:30 am ET) to discuss its half year 2022 financial results and provide a second quarter business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the call.
Dial-in numbers:
Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.
Belgium 32 800 50 201
United Kingdom 44 800 358 0970
United States 1 888 415 4250
All other locations 1 929 526 1599
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:
Kelsey Kirk
kkirk@argenx.com
Investors:
Beth DelGiacco
bdelgiacco@argenx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.